Soraa’s LED Lighting Perfectly Illuminates Crosswater Showroom
Soraa, the world leader in GaN on GaNTM LED technology, announced that its LED lamps have been installed at the new Crosswater UK showroom, one of the largest bathroom showrooms in Europe. Investing in a new headquarters with a beautifully-appointed showroom gallery in Dartford, Kent, Crosswater wanted lighting to enhance a memorable experience for visitors as they moved through the showroom to discover innovative bathroom designs and superior quality products available for today’s home design.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160114005989/en/
Inside the beautifully-appointed Crosswater showroom gallery in Dartford, Kent with Soraa LED lights. (Photo: Business Wire)
To create drama while not overwhelming guests, the lighting needed to create a sense of space, curate visitor traffic flow, and perfectly illuminate the 32 beautifully designed bathroom vignettes in the showroom. Architects Coppin Dockray and lighting designers from Lightplan chose Soraa LED lamps because of their unique ability to deliver narrow beams and perfect rendering of colours and whiteness. Specifically, Lightplan chose 635 of Soraa’s MR16 LED lamps mounted within Prospex® Spot Midi 2100-MR-SP fixtures from Lucent®, a Works With Soraa partner. The Prospex die-cast aluminium fixtures come with integral control gear and their adjustable heads accept up to two accessories held behind an anti-glare snoot.
Visitors are guided through the Crosswater showroom space by a stunning “swirling walkway” of approximately 5,800 hand-blown glass spheres that hang from the ceiling and are perfectly illuminated by Soraa’s LED lamps. Because Soraa LED lamps cast strong, narrow beams from a small source, Lightplan was able to spotlight the beautiful glass spheres without light spilling over onto merchandise displays – even as a control system creates a moving effect among the baubles.
“Soraa lighting makes the journey through the showroom a sensory experience for visitors. Because Soraa LED lamps provide a high intensity beam from a small source, we were able to create perfect, focused lighting on the fixtures and objects on display in each of the 32 uniquely appointed bathroom display areas. The snap on attachments, spreader lenses, are great tools to shape the light beam for a particular object preventing any spillage,” said Baris Gursen, lighting designer with Lightplan in London.
The porcelain, tiles, textiles and wallpaper throughout Crosswater’s perfectly-designed bathroom interior displays also needed Soraa’s perfect lighting. With Soraa’s Violet-Emission 3-Phosphor (VP₃) LED lamp technology, Lightplan was also able to beautifully illuminate very specific architectural objects and fixtures with truer colours and varying light intensities. Utilising every colour in the rainbow, especially deep red emission, Soraa’s lamps render warm tones beautifully and accurately with a colour-rendering index (CRI) of 95 and deep red (R9) rendering of 95. And unlike blue-based white LEDs without any violet emission, Soraa’s lamps have violet emissions to properly excite fluorescing brightening agents found in elements, such as white fixtures and tiles.
“Perfect design requires perfect lighting. Soraa lamps helped us illuminate our Crosswater products and display rooms as art. Every visitor to our showroom is stunned by the beauty of the space and our designs,” said Nico de Beer, Director. Crosswater UK.
For more information on Soraa’s LED lamps, please visit: www.soraa.com.
Lighting design credit: Lightplan, London
Architecture design credit: Coppin Dockray, London
Pioneering lamps using LEDs built from pure gallium nitride substrates (GaN on GaN™), Soraa has made ordinary lighting extraordinarily brilliant and efficient. Soraa’s full spectrum GaN on GaN™ LED lamps have superior colour rendering and beam characteristics compared to lamps using LEDs created from non-native substrates. Founded in 2008, Soraa is located in Fremont California, where it manufactures its GaN on GaN™ LEDs in the company’s state-of-the-art facility. For additional information, please visit www.soraa.com and follow the company on Twitter, LinkedIn and Facebook.
Andy Beck, 001-202-587-5634
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom